COMPANY

Myosin Therapeutics Inc.

HQ: Jupiter, FL source · myosintherapeutics.com ↗ · Southeast

Location: Jupiter, FL · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Glioblastoma MT-125

Funding and NIH signals

NIH award NIH awarded $2.24M (SBIR Phase II 5R44CA278293-05, continuation, notice Sep 17, 2026). NIH RePORTER 5R44CA278293-05 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 5R44CA278293-05
  Organization: MYOSIN THERAPEUTICS INC.; City/State: JUPITER, FL; Project number: 5R44CA278293-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 2241448; Administering IC: National Cancer Institute; Project title: Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Sep 17, 2026 Grant Government grant — SBIR: $2.24M (annual award, as published), announced Sep 17, 2026. Agency: NIH/NCI. Source: government award database. source ↗
2026-07 Trial start 1: A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma source ↗
Apr 1, 2026 Trial start 1: A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients source ↗
Sep 16, 2025 Grant Government grant — SBIR: $249,417 (annual award, as published), announced Sep 16, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Aug 7, 2025 Grant Government grant — SBIR: $2.25M (annual award, as published), announced Aug 7, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Mar 18, 2025 Grant Government grant — SBIR: $1.5M (annual award, as published), announced Mar 18, 2025. Agency: NIH/NIDA. Source: government award database. source ↗
Jan 8, 2025 Grant Government grant — STTR: $911,407 (annual award, as published), announced Jan 8, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Oct 31, 2026 (ESTIMATED) · 1 · A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients · NCT07185880
2027-03 (ESTIMATED) · 1 · A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma · NCT07604285

Estimated primary completion per ClinicalTrials.gov. Dates move.

Last 2 years.

Sep 17, 2026 Government grant — SBIR: $2.24M (annual award, as published), announced Sep 17, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 16, 2025 Government grant — SBIR: $249,417 (annual award, as published), announced Sep 16, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Aug 7, 2025 Government grant — SBIR: $2.25M (annual award, as published), announced Aug 7, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Mar 18, 2025 Government grant — SBIR: $1.5M (annual award, as published), announced Mar 18, 2025. Agency: NIH/NIDA. Source: government award database. source ↗
Jan 8, 2025 Government grant — STTR: $911,407 (annual award, as published), announced Jan 8, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07604285	A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma	1	Not yet recruiting	2026-07	2027-03 (estimated)
NCT07185880	A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients	1	Recruiting	Apr 1, 2026	Oct 31, 2026 (estimated)

Annual award amounts. Total $4.9M.

Jan 16, 2024 NIH award 4R42CA278293-02 FY2024: $1,348,593 awarded for that fiscal year; activity R42 (STTR); PI ROSENFELD, STEVEN S; recipient as written: MYOSIN THERAPEUTICS INC., JUPITER, FL. MT-125 for the Therapeutic Treatmen source ↗
Aug 9, 2023 NIH award 5R44DA055420-03 FY2023: $1,208,298 awarded for that fiscal year; activity R44 (SBIR); PI YOUNG, ERICA J; recipient as written: MYOSIN THERAPEUTICS INC., JUPITER, FL. Development of a first-in-class nonmuscl source ↗
Apr 14, 2023 NIH award 3R44DA055420-02S1 FY2023: $440,888 awarded for that fiscal year; activity R44 (SBIR); PI YOUNG, ERICA J; recipient as written: MYOSIN THERAPEUTICS INC., JUPITER, FL. Development of a first-in-class nonmuscl source ↗
Mar 31, 2023 NIH award 1R42CA278293-01A1 FY2023: $406,500 awarded for that fiscal year; activity R42 (STTR); PI ROSENFELD, STEVEN S; recipient as written: MYOSIN THERAPEUTICS INC., JUPITER, FL. MT-125 for the Therapeutic Treatmen source ↗
Aug 11, 2022 NIH award 4R44DA055420-02 FY2022: $1,208,298 awarded for that fiscal year; activity R44 (SBIR); PI YOUNG, ERICA J; recipient as written: MYOSIN THERAPEUTICS INC., JUPITER, FL. Development of a first-in-class nonmuscl source ↗
Sep 21, 2021 NIH award 1R44DA055420-01 FY2021: $325,429 awarded for that fiscal year; activity R44 (SBIR); PI YOUNG, ERICA J; recipient as written: MYOSIN THERAPEUTICS INC., JUPITER, FL. Development of a first-in-class nonmuscle source ↗